Join us for a virtual KOL event with Compugen, featuring Drew Pardoll, M.D., Ph.D., Professor of Oncology, Johns Hopkins University, and Chairman of Compugen’s Scientific Advisory Board, who will discuss the biological mechanistic rationale behind Compugen’s differentiated DNAM-1 axis hypothesis suggesting the simultaneous blockade of PVRIG, TIGIT and PD-1 has the potential to synergistically enhance anti-tumor immune responses in selected patient populations who are not responsive or refractory to PD-1 blockers alone.

A short introductory presentation will be provided by Compugen’s SVP Research and Drug Discovery, Eran Ophir, Ph.D., followed by a discussant presentation by Dr. Pardoll.

A live question and answer session with Dr. Pardoll and members of Compugen’s leadership team will follow the formal presentations.